When GPs Can Prescribe Mounjaro: The NHS Rollout Explained

What NICE actually approved — and when

The starting point is NICE technology appraisal TA1026, published on 23 December 2024. That document formally recommended tirzepatide (Mounjaro) for NHS use in adults with a BMI of 35 or above and at least one weight-related comorbidity, or at proportionally lower BMI thresholds for some ethnic backgrounds. The appraisal set the clinical logic; it did not set the start date. NHS England then took that recommendation and built a phased commissioning structure around it, because demand for GLP-1 medicines vastly outstrips current supply and specialist-service capacity.

What followed was a staged rollout rather than an open door. Cohort 1 began in June 2025, but only for patients with a BMI of 40 or above plus four or more of a defined list of five conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. That is a narrow window. Most people who would benefit clinically do not meet all four-plus conditions simultaneously.

GP-level prescribing then unlocked formally on 1 April 2026 as part of the 2026/27 QOF contract. Before that date, NHS access was routed entirely through specialist weight-management services.

GP prescribing from April 2026: what changed, and what didn't

From 1 April 2026, GP practices in England that opted into the new arrangements gained the contractual ability to prescribe Mounjaro for eligible patients. The word "opted" matters. GP participation is not mandatory, so whether your practice can prescribe it depends on whether your surgery has signed up, whether your local integrated care board has activated the service, and whether you meet the current cohort criteria.

Cohort 2 activated on 23 June 2026, extending NHS eligibility to patients with a BMI of 35–39.9 plus four or more of the five qualifying conditions. The next expansion, expected around March 2027, is expected to include BMI of 40-plus with three or more conditions. Each broadening of criteria is conditional on supply, NHS capacity and budget sign-off, none of those dates are fixed guarantees.

Every NHS patient must also take part in approved wraparound dietary and activity support alongside treatment. Meeting the BMI and comorbidity numbers is necessary but not on its own sufficient. If you are wondering whether your GP will actually prescribe Mounjaro for you given your specific circumstances, that question is worth exploring before your appointment. For a clearer picture of how GP prescribing works in practice, the full picture of GP prescribing and what it involves is worth reading alongside this page. NHS England's detailed guidance for GPs is published at NHS England's tirzepatide-in-primary-care page.

What this means if you don't qualify yet, or don't want to wait

For a significant number of people, the current NHS cohort remains out of reach. A BMI of 38 with hypertension and high cholesterol (two conditions, not four) puts you outside Cohort 2 even if you are exactly the kind of patient Mounjaro was trialled on. The SURMOUNT-1 trial enrolled adults with obesity and no diabetes requirement; thousands saw meaningful weight reduction over 72 weeks. The NHS criteria are a rationing decision, not a clinical one.

That gap between what the evidence supports and what the NHS currently funds is why private prescribing exists. Mounjaro's licensed eligibility for private prescription is broader: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. A GPhC-registered prescriber assesses the whole picture, not a checklist of four comorbidities. If you'd like to understand the cost side of private treatment, the Mounjaro private price comparison sets out what legitimate pricing typically covers.

Scotland, Wales and Northern Ireland each run their own commissioning arrangements with different thresholds and timelines, so if you are outside England, it is worth checking locally. The broader NHS availability picture covers the devolved nations briefly. For England, what changed at the June 2025 launch explains how Cohort 1 got under way.

The private route: how it works right now

None of this affects what's legally available to you privately today. Mounjaro is a prescription-only medicine, so any legitimate route (NHS or private) requires a clinical assessment and a prescription. The difference is that a private prescriber applies the manufacturer's licensed criteria rather than the NHS commissioning thresholds, and there is no waiting list built into the process.

At nume, a GPhC-registered Independent Prescriber personally reviews every consultation the same day. If you order before 12pm on a working day and are clinically approved, your treatment is dispatched that afternoon and arrives the next working day via DPD, in plain unbranded packaging. No subscription is set up automatically; every repeat is clinically re-reviewed. You can verify our pharmacy on the GPhC register directly: registration number 9012878 at pharmacyregulation.org.

If you're weighing up whether the NHS route or the private route makes more sense for your situation, a useful starting point is reading about whether the NHS will prescribe Mounjaro and under what circumstances before speaking to your GP. Our prescribers are also available through our weight-loss treatment overview if you want to understand the wider options first.